Company Overview and News
REVIEW: Bursa Malaysia in the post-election week reflected investor sentiment over the polling results with a show of confidence by local institutions keeping the market in good stead.
The unprecedented electoral victory by Pakatan Harapan was unfavourable to many stocks as it was favourable to others.
PETALING JAYA: Ahmad Zaki Resources Bhd (AZRB) has been awarded a RM197.96mil construction contract by PNB Merdeka Ventures Sdn Bhd.
PETALING JAYA: With the Government expected to make announcements on changes to toll charges on expressways, attention will be focused on the impact this may have on concessionaires and the national finances.
PETALING JAYA: Several politically-linked stocks on Bursa Malaysia went on a wild ride yesterday, driven by the market volatility in the first day of trading post-14th general election (GE14).
Possible M&A: Shareholding changes suggest that Alliance Bank could be poised for an M&A down the road.
KUALA LUMPUR: Asia Poly Holdings Bhd , Muhibbah Engineering (M) Bhd , Ahmad Zaki Resources Bhd and Daya Materials Bhd are among the stocks to watch on Friday according to JF Apex Research.
KUALA LUMPUR, Dec 21 ― Ahmad Zaki Resources Bhd (AZRB) said that its wholly-owned subsidiary, Ahmad Zaki Sdn Bhd has received and accepted a Letter of Award from Institute of Technology Petronas Sdn Bhd for a construction project.
Tags / Keywords: Construction , Mass Rapid Transit Corp Bhd , Ahmad Zaki Resources Bhd , Malaysian Resources Corp Bhd
MarketWatch: US stocks retreated from recent record highs on Thursday as AT&T shares sank after it said it lost subscribers in the last quarter and banks slipped following results from JPMorgan and Citigroup. The DJIA fell 31.88 points, or 0.14%, to end at 22,841.01, the S&P 500 lost 4.31 points, or 0.17%, to 2,550.93 and the Nasdaq dropped 12.04 points, or 0.18%, to 6,591.51. - Reuters
PETALING JAYA: Sunway Construction Group Bhd (SunCon) has secured a RM74.77mil contract from Ahmad Zaki Resources Bhd to provide earthworks and piling services.
KUALA LUMPUR (April 12): The FBM KLCI is expected to remain lacklustre today in line with the tepid overnight sentiment at most global markets, as geopolitical jitters appear to be gaining traction.
KUALA LUMPUR (April 11): Based on corporate announcements and news flow today, companies that might be in focus on Wed (April 12) include the following: AZRB, Protasco, Tenaga, Thriven, Mulpha, Vsolar, mTouche, Globetronics, PUC Founder and Ire-Tex. Ahmad Zaki Resources Bhd (AZRB) has secured a two-year service contract for the provision of crew boat activity and other support services at the Tok Bali Supply Base in Kelantan.
KUALA LUMPUR (March 31): Based on corporate announcements and news flow today, stocks in focus on Monday (April 3) may include: Sapura Energy Bhd, AirAsia Bhd, Ahmad Zaki Resources Bhd, Master-Pack Group Bhd, Globetronics Technology Bhd, ATTA Global Group Bhd, Vizione Holdings Bhd, Nexgram Holdings Bhd, Borneo Oil Bhd, Inix Technologies Holdings Bhd, Kerjaya Prospek Group Bhd, Eversafe Rubber Bhd and Mulpha International Bhd
KUALA LUMPUR (March 8): The FBM KLCI moved south at the midday break, in line with the regional markets that trended lower, as sellers outpaced buyers. At 12.30pm, the FBM KLCI fell 1.96 point to 1,726.70.
2018-05-19 - Asif
OVERVIEW Sangamo BioSciences is a clinical stage biotechnology company focused on translating ground-breaking science into genomic therapies that transform patients’ lives using its industry-leading platform technologies in genome editing, gene therapy, gene regulation and cell therapy. Sangamo BioSciences is a leader in the research and development of zinc finger proteins, or ZFPs, a naturally occurring class of proteins found in humans. Sangamo BioSciences has used its knowledge and expertise to develop a proprietary technology platform in both genome editing and gene regulation. ZFPs can be engineered to make zinc finger nucleases, or ZFNs, proteins that can be used to specifically modify DNA sequences by adding or knocking out specific genes, or genome editing, and ZFP transcription factors or ZFP TFs, proteins that can be used to increase or decrease gene expression, or gene regulation. In the process of developing this platform, Sangamo BioSciences has accrued signific...
2018-05-19 - Asif
Business Overview The company provide high quality information technology, or IT, services and solutions including a range of technology platforms focusing on big data, business intelligence, and consumer-centric technology. More recently, to provide greater value to stockholders, the Company has sought to expand its business primarily through acquisitions that leverage its capabilities and expertise. As of March 31, 2018, the Company owned 81.2%, and as of the date of this report the Company owns 91.8%, of the outstanding shares of MoviePass (excluding outstanding MoviePass options and warrants). MoviePass is the premiere movie theater subscription service in the United States which provides its subscribers the ability to view up to one new movie title per day for one monthly subscription price. The company's more than 2 million subscribers have access to see films in over 91% of U.S movie theaters. By the end of April 2018, the company implemented certain measures ...
2018-05-17 - Asif
Overview Biostage is a biotechnology company developing bioengineered organ implants based on its novel CellframeTM technology. The company's Cellframe technology is comprised of a biocompatible scaffold that is seeded with the recipient’s own stem cells. This technology is being developed to treat life-threatening conditions of the esophagus, trachea or bronchus with the objective of dramatically improving the treatment paradigm for those patients. The company believe that its Cellframe technology will provide surgeons with new ways to address damage to the esophagus, bronchus, and trachea due to congenital abnormalities, cancer, infection or trauma. Products being developed based on its Cellframe technology for those indications are called CellspanTM products. The company announced favorable preliminary pre-clinical results of large-animal studies for the esophagus, trachea and bronchus in November 2015. Since then, the Cellspan esophageal implant product candidates hav...